Treatment of Acute Promyelocytic Leukemia with High White Cell Blood Counts.

por Kelaidi, C., Adès, L., Fenaux, P.
Publicado 2011

Analysis of p16 gene deletion and point mutation in breast carcinoma.

por Quesnel, B., Fenaux, P., Philippe, N., Fournier, J., Bonneterre, J., Preudhomme, C., Peyrat, J. P.
Publicado 1995

Relationship of different platelet response criteria and patient outcomes in a romiplostim myelodysplastic syndromes trial

por Platzbecker, U, Sekeres, M A, Kantarjian, H, Giagounidis, A, Mufti, G J, Jia, C, Yang, A S, Fenaux, P
Publicado 2014

PB2352: CONSOLIDATION OF ERN-EUROBLOODNET: THE EUROPEAN REFERENCE NETWORK ON RARE HEMATOLOGICAL DISEASES FIRST 5 YEARS OF IMPLEMENTATION

por Mañú Pereira, M. D. M., Gutierrez Valle, V., Pellegrini, M., Rodríguez Sánchez, M. D. L. Á., Margot, L., Gulbis, B., Fenaux, P.
Publicado 2022

Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis

por Kuendgen, A, Lauseker, M, List, A F, Fenaux, P, Giagounidis, A A, Brandenburg, N A, Backstrom, J, Glasmacher, A, Hasford, J, Germing, U
Publicado 2013

Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)

por Sekeres, M A, Swern, A S, Fenaux, P, Greenberg, P L, Sanz, G F, Bennett, J M, Dreyfus, F, List, A F, Li, J S, Sugrue, M M
Publicado 2014

The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update

por Silverman, LR, Fenaux, P, Mufti, GJ, Santini, V, Hellström-Lindberg, E, Gattermann, N, Sanz, G, List, AF, Gore, SD, Seymour, JF, Backstrom, J, McKenzie, D, Beach, CL
Publicado 2008

1721P Prolonged positive SARS-CoV-2 RT-PCR in cancer outpatients requires specific reorganization of cancer centres

por Aguinaga, L., Ursu, R., Legoff, J., Delauguerre, C., Nguyen, O., Harel, S., Royer, B., sebert, M., Jachiet, M., Lebbé, C., Bonnet, C., Brice, P., Fenaux, P., Plaud, B., Aparicio, T.
Publicado 2020

Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an...

por Fenaux, P, Mufti, GJ, Hellström-Lindberg, E, Santini, V, Gattermann, N, Sanz, G, List, AF, Gore, SD, Seymour, JF, Backstrom, J, Zimmerman, L, McKenzie, D, Beach, CL, Silverman, LB
Publicado 2008

pVAX14DNA-mediated add-on immunotherapy combined with arsenic trioxide and all-trans retinoic acid targeted therapy effectively increases the survival of acute promyelocytic leukem...

por Patel, S, Guerenne, L, Gorombei, P, Omidvar, N, Schlageter, M-H, Alex, A A, Ganesan, S, West, R, Adès, L, Mathews, V, Krief, P, Pla, M, Fenaux, P, Chomienne, C, Padua, R A
Publicado 2015

Preclinical modeling of myelodysplastic syndromes

por Rouault-Pierre, K, Mian, S A, Goulard, M, Abarrategi, A, Di Tulio, A, Smith, A E, Mohamedali, A, Best, S, Nloga, A-M, Kulasekararaj, A G, Ades, L, Chomienne, C, Fenaux, P, Dosquet, C, Mufti, G J, Bonnet, D
Publicado 2017

Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents

por Duchmann, M, Braun, T, Micol, J-B, Platzbecker, U, Park, S, Pilorge, S, Beyne-Rauzy, O, Vey, N, Sébert, M, Gruson, B, Dumas, P-Y, Guieze, R, Chretien, M-L, Laribi, K, Chait, Y, Legros, L, Sahnes, L, Hirsch, P, Salanoubat, C, Solary, E, Fenaux, P, Itzykson, R
Publicado 2017

Erythropoiesis‐stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower‐risk myelodysplastic syndrome

por Garelius, H. K. G., Johnston, W. T., Smith, A. G., Park, S., de Swart, L., Fenaux, P., Symeonidis, A., Sanz, G., Čermák, J., Stauder, R., Malcovati, L., Mittelman, M., van de Loosdrecht, A. A., van Marrewijk, C. J., Bowen, D., Crouch, S., de Witte, T. J. M., Hellström‐Lindberg, E.
Publicado 2016

PB1921: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF TAMIBAROTENE/AZACITIDINE VERSUS PLACEBO/AZACITIDINE IN NEWLY DIAGNOSED ADULT PATIENTS SELECTED FOR RARA-POSITIVE HR-MDS (SELECT...

por DeZern, A., Marconi, G., Deeren, D., Diez Campelo, M., Lübbert, M., Krishnamurthy, P., Nagy, Z., Basak, G., Jonášová, A., Morozova, E., Geissler, K., Ofran, Y., Kelley, H., Volkert, A., Baker, K., Kang-Fortner, Q., Hodgson, G., Madigan, C., Roth, D. A., Kelly, M., Fenaux, P.
Publicado 2022

An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies

por Padron, E, Garcia-Manero, G, Patnaik, M M, Itzykson, R, Lasho, T, Nazha, A, Rampal, R K, Sanchez, M E, Jabbour, E, Al Ali, N H, Thompson, Z, Colla, S, Fenaux, P, Kantarjian, H M, Killick, S, Sekeres, M A, List, A F, Onida, F, Komrokji, R S, Tefferi, A, Solary, E
Publicado 2015

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts

por Garcia-Manero, G, Sekeres, M A, Egyed, M, Breccia, M, Graux, C, Cavenagh, J D, Salman, H, Illes, A, Fenaux, P, DeAngelo, D J, Stauder, R, Yee, K, Zhu, N, Lee, J-H, Valcarcel, D, MacWhannell, A, Borbenyi, Z, Gazi, L, Acharyya, S, Ide, S, Marker, M, Ottmann, O G
Publicado 2017

Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial

por Kubasch, A. S., Peterlin, P., Cluzeau, T., Götze, K. S., Sockel, K., Teipel, R., Jentzsch, M., Attalah, H., Sebert, M., Chermat, F., Gloaguen, S., Puttrich, M., Cross, M., Schneider, M., Kayser, S., Schipp, D., Giagounidis, A., Tirado-Gonzalez, I., Descot, A., van de Loosdrecht, A., Weigert, A., Metzeler, K. H., Fenaux, P., Medyouf, H., Platzbecker, U., Ades, L.
Publicado 2023